망막혈관종성증식 환자에서 유리체강내 항혈관내피세포성장인자 주입술의 12개월 임상결과

• 영문명: Twelve-Month Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation
• 발행기관: 대한안과학회
• 저자명: 김덕배 김재휘 정성헌 이태곤 김종우 김철구 조성원 이동원 한정일,Deok Bae Kim, MD, Jae Hui Kim, MD, Seong Hun Jeong, MD, Tae Gon Lee, MD, Jong Woo Kim, MD,Chul Gu Kim, MD, Sung Won Cho, MD, Dong Won Lee, MD, Jung Il Han, MD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume54,number11, 1700~1707쪽, 전체 8쪽
• 주제분류: 인문학 > 역사학
• 파일형태: PDF
• 발행일자: 2013.11.15

영문 초록

Purpose: To evaluate the 12-month outcomes of anti-vascular endothelial growth factor (VEGF) treatment for patients with retinal angiomatous proliferation (RAP). Methods: Retrospective review of medical records was performed for 33 patients (33 eyes) who were diagnosed with RAP. All patients were initially treated with three consecutive intravitreal anti-VEGF injections after diagnosis. Additional treatment was performed when the recurrence of exudation was noted. The best-corrected visual acuity (BCVA) was measured before the first injection and at 3, 6, and 12 months after the first injection. The value measured before the treatment was compared with those measured after treatment. Results: The patients received an average of 4.2 ± 1.7 intravitreal anti-VEGF injections during the 12-month follow-up period. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and at 3, 6, and 12 months after the first injections were 0.76 ± 0.49, 0.55 ± 0.35, 0.67 ± 0.41, and 0.70 ± 0.50, respectively. BCVA was significantly improved at 3 and 6 months (p < 0.001 and p = 0.037) compared to that measured before the first injection. However, there was no significant difference between BCVA before the first injection and 12 months after the first injection (p = 0.590). At 12 months of follow-up, 29 eyes (87.9%) showed stable (<2 log MAR lines of change) or improved (≥2 log MAR lines of improvement) BCVA. Conclusions: Anti-VEGF therapy was found to be beneficial in both normalizing macular thickness and in improving or maintaining visual acuity in the majority of patients with RAP. J Korean Ophthalmol Soc 2013;54(11):1700-1707

키워드

Anti-vascular endothelial growth factor, Clinical outcomes, Retinal angiomatous proliferation, Visual acuity